Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  daratumumab
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104762, NCI-2015-01114, 2014-002273-11, NCT02252172
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR106626, NCI-2015-01138, 54767414MMY3010, NCT02477891
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR107838, NCI-2016-00594, 2015-001210-94, 54767414MMY1004, NCT02519452
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MEDI4736-MM-003, NCI-2016-01253, NCT02807454
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CR106449, NCI-2015-01089, 2014-005139-14, NCT02316106
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CR106660, NCI-2015-01142, 54767414LYM2001, NCT02413489
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, NCT01998971
Start Over